RECRUITING

Alzheimer's National Registry for Treatment and Diagnostics(ALZ-NET)

Talk to us

Conditions

Alzheimer DiseaseAlzheimer's DiseaseDementiaBrain DiseasesCentral Nervous System DiseasesNervous System DiseasesTauopathiesNeurodegenerative DiseasesNeurocognitive DisordersTrialsMild Cognitive Impairment

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The Alzheimer's Network for Treatment and Diagnostics (ALZ-NET) will collect longitudinal clinical and safety data for enrolled patients being evaluated for or treated with novel FDA-approved Alzheimer's disease (AD) therapies. ALZ-NET is a longitudinal registry with an expandable platform, designed to grow with scientific and medical advancements. As new treatments are approved and implemented in care, ALZ-NET will track the long-term health outcomes associated with their use in a real-world setting. ALZ-NET is a resource for evidence gathering, information sharing and education across clinical and research communities, encouraging innovative research and supporting opportunities to improve clinical care delivery. All participating physicians and site staff will complete comprehensive training to ensure adherence of data requirements and registry timelines.

Official Title

Alzheimer's National Registry for Treatment and Diagnostics

Quick Facts

Study Start:2022-10-20
Study Completion:2032-12
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT06170268

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Patient or patient's legally authorized representative (LAR) or proxy (e.g., spouse or legal guardian) has the ability to understand the purpose and risks of ALZ-NET and provide signed and dated informed consent and authorization to use protected health information (PHI) in accordance with national and local patient privacy regulations.
  2. * Patient is at least 18 years of age at the time of informed consent.
  3. * Patient has a diagnosis of MCI or dementia with clinical suspicion of AD as contributing pathology and (1) is being evaluated for treatment or, (2) will be initiating treatment, or (3) has already initiated treatment with novel FDA-approved AD therapies in real-world clinical practice.
  4. * If treatment is initiated at the time of consent, patient meets appropriate label requirements and treatment follows appropriate use recommendations for novel FDA-approved AD therapy/therapies.
  5. * Patient's treating clinician has made the decision to provide clinical care or treatment prior to patient consent and independently of the purpose of ALZ-NET.
  1. Pregnancy or breastfeeding
  2. Severe psychiatric disorders
  3. Active substance abuse
  4. Unstable medical conditions
  5. Inability to comply with study requirements

Contacts and Locations

Study Contact

ALZ-NET Operations Team
CONTACT
215-574-3181
alz-net@acr.org
ALZ-NET Scientific Team
CONTACT
alzheimersnetwork@alz.org

Principal Investigator

Gil Rabinovici, MD
PRINCIPAL_INVESTIGATOR
University of California, San Francisco
Maria C Carillo, PhD
PRINCIPAL_INVESTIGATOR
Alzheimer's Association
Michael S Rafii, MD, PhD
PRINCIPAL_INVESTIGATOR
University of Southern California

Study Locations (Sites)

Full List of Active Sites
Chicago, Illinois, 60601
United States

Collaborators and Investigators

Sponsor: Alzheimer's Disease and Related Disorders Association, Inc

  • Gil Rabinovici, MD, PRINCIPAL_INVESTIGATOR, University of California, San Francisco
  • Maria C Carillo, PhD, PRINCIPAL_INVESTIGATOR, Alzheimer's Association
  • Michael S Rafii, MD, PhD, PRINCIPAL_INVESTIGATOR, University of Southern California

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2022-10-20
Study Completion Date2032-12

Study Record Updates

Study Start Date2022-10-20
Study Completion Date2032-12

Terms related to this study

Keywords Provided by Researchers

  • Alzheimer's Disease
  • Dementia
  • Brain Diseases
  • Central Nervous System Diseases
  • Nervous System Diseases
  • Tauopathies
  • Neurodegenerative Diseases
  • Neurocognitive Disorders
  • Trials
  • Mild Cognitive Impairment

Additional Relevant MeSH Terms

  • Alzheimer Disease